XML 31 R21.htm IDEA: XBRL DOCUMENT v3.21.2

Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)

9 Months Ended

Sep. 30, 2021

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Liabilities at Fair Value

The following table presents the changes in the development derivative liability for the three and nine months ended September 30, 2021:

						Three Months Ended September 30, 2021						Nine Months Ended September 30, 2021
Fair value at beginning of period						$	11,607					$	—
Non-cash research and development expense						5,702						11,497
Cash receipts from SFJ						750						2,250
Change in the fair value of development derivative liability						3,328						7,640
Fair value at end of period						$	21,387					$	21,387

X

- References

No definition available.

+ Details

Name:	us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of derivative liabilities at fair value.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration